August 2012
-
An innovative, inhalation-focused development organisation with multiple UK sites is now looking for an Analytical Development Manager at their modern facility in the southwest of the UK. The successful candidate will lead an experienced team… Read more . . .
-
The laboratory groups at Catalent RTP are responsible for the support of pharmaceutical product development in a range of dosage forms both directly with customers and in collaboration with other Catalent facilities. This includes formulation… Read more . . .
-
The laboratory groups at Catalent RTP are responsible for the support of pharmaceutical product development in a range of dosage forms both directly with customers and in collaboration with other Catalent facilities. This includes formulation… Read more . . .
-
Numerous studies have described the difficulties patients experience in using metered dose inhalers (MDIs), including a recent article in the Journal of General Internal Medicine (JGIM) that found 86% of hospitalized patients enrolled in a… Read more . . .
-
Chuck Bramlage has been appointed President and Chief Executive Officer of Pearl Therapeutics, replacing interim President and CEO Howard Rosen. Pearl, a California pharmaceutical company developing inhaled treatments for COPD and asthma, was founded in… Read more . . .
-
On the second day of the Drug Delivery to the Lungs meeting in December 2010 (DDL 21), Xiang Kou, a grad student from the National University of Singapore who had been spending time as a… Read more . . .
-
The Impactor Sub-Team of the European Pharmaceutical Aerosol Group (EPAG), a consortium of pharmaceutical companies that develop pulmonary and intranasal drugs, has focused its attention on the potential benefits of the abbreviated impactor method (AIM),… Read more . . .
-
At the next IPAC-RS conference, March 29-31 in Rockville, MD, sponsored by the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS), OINDP specialists will have uncommon opportunities to interact with regulators, representatives of patient… Read more . . .
-
On Friday, December 10, just as the snow was beginning to melt in Edinburgh, DDL 21 concluded with one last podium session. Delegates also had a chance to spend some additional time at the exhibition.… Read more . . .
-
The second day of DDL 21 offered a wide variety of presentations, a focus on young investigators and the presentation of several awards, in addition to a continuation of the exhibition. By Day 2, most… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland